Loratadine Blockade of K+ Channels in Human Heart: Comparison with Terfenadine under Physiological Conditions

  1. William J. Crumb, Jr.
  1. Department of Pediatrics, Division of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana

    Abstract

    Recently, there has been considerable attention focused on drugs that prolong the QT interval of the electrocardiogram, with the H1-receptor antagonist class of drugs figuring prominently. Albeit rare, incidences of QT prolongation and ventricular arrhythmias, in particular torsade de pointes, have been reported with the antihistamines astemizole and terfenadine and more recently with loratadine. The most likely mechanism for these drug-related arrhythmias is blockage of one or more ion channels involved in cardiac repolarization. Several studies have demonstrated block of multiple cardiac K+ channels by terfenadine, includingIto, Isus,IK1, and IKr or human ether-a-go-go-related gene (HERG). In contrast to terfenadine, previous studies have shown the antihistamine loratadine to be virtually free of cardiac ion channel-blocking effects. This disparity in the lack of any significant cardiac ion channel-blocking effect and the existence of numerous adverse cardiac event reports for loratadine prompted the comparison of the human cardiac K+channel-blocking profile for loratadine and terfenadine under physiological conditions [37°C, holding potential (Vhold) = −75 mV] with the whole-cell patch-clamp method. Isolated human atrial myocytes were used to examine drug effects on Ito,Isus, and IK1, whereas HERG was studied in stably transfected HEK cells. In contrast to previous studies in nonhuman systems and/or under nonphysiological conditions, terfenadine (1 μM) had no effect onIto, Isus, orIK1 at pacing rates up to 3 Hz. Similar results were found for 1 μM loratadine. However, both drugs potently blocked HERG current amplitude, with a mean IC50 of 173 nM for loratadine and 204 nM for terfenadine (pacing rate, 0.1 Hz). Neither drug exhibited any significant use-dependent blockage of HERG (pacing rates = 0.1–3 Hz). These results point to a similarity in the human cardiac K+ channel-blocking effects of loratadine and terfenadine and provide a possible mechanism for the arrhythmias associated with the use of either drug.

    Footnotes

    • Send reprint requests to: William J. Crumb, Jr., Ph.D., Department of Pediatrics, Division of Cardiology, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA 70112-2699. E-mail: wcrumb{at}tmcpop.tmc.tulane.edu

    • Abbreviations:
      HERG
      human ether-a-go-go-related gene
      DMSO
      dimethyl sulfoxide
      ERG
      ether-a-go-go-related gene
      • Received May 17, 1999.
      • Accepted August 31, 1999.
    « Previous | Next Article »Table of Contents